• NeOnc Technologies reported early clinical improvement in its first child treated with investigational NEO100 under compassionate use in Abu Dhabi.
• The three-year-old boy with an aggressive brain tumor is breathing without ventilator support, according to treating physicians.
• Physicians also reported emerging leg movement following treatment with the intranasal drug.
• Treatment occurred outside the NEO100-03 pediatric trial because the child did not meet eligibility criteria.
• The single-patient observations do not establish that NEO100 caused improvement; pediatric safety and efficacy remain unproven.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610160800PRIMZONEFULLFEED9847003) on October 16, 2026, and is solely responsible for the information contained therein.